Michael Gelband’s Nautilus Biotechnolgy NAUT Stock Holding History

Michael Gelband’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-137,826	Closed	-$598K	–	2261
2022 Q1	$598K	Buy	+137,826	New	+$566K	0.01%	1432
2021 Q4	–	Sell	-13,438	Closed	-$83K	–	2452
2021 Q3	$83K	Buy	+13,438	New	+$107K	﹤0.01%	1926
2021 Q1	–	Sell	-10,000	Closed	-$108K	–	2430
2020 Q4	$108K	Buy	+10,000	New	+$105K	﹤0.01%	1824

Other funds holding NAUT

AEPBI

AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Michael Gelband's NAUT Position: Q2 2022 in Review

Michael Gelband sold out of Nautilus Biotechnolgy (NAUT) in Q2 2022, closing a stake of 137,826 shares — an estimated $598K sold.

Michael Gelband first reported a position in NAUT in Q4 2020 and held it in 3 quarters. The position peaked at $598K in Q1 2022. 83 funds tracked by Wall St. Rank hold NAUT as of Q2 2022.

Michael Gelband reported no remaining Nautilus Biotechnolgy position as of Q2 2022 after selling out during the quarter.
Michael Gelband sold 137,826 Nautilus Biotechnolgy shares in Q2 2022, an estimated $598K.
Michael Gelband first reported a position in Nautilus Biotechnolgy in Q4 2020 and held it in 3 quarters.
Michael Gelband's Nautilus Biotechnolgy position peaked at $598K in Q1 2022.
83 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.